FDA approves Glaxo's GLP-1

Share this article:

GlaxoSmithKline's weekly GLP-1 diabetes injection has been approved. The FDA made the announcement Tuesday morning. The type-2 diabetes drug, known in past coverage as albiglutide, is officially called Tanzeum.

The FDA was initially set to review the drug in January but said last August that it needed more time to review “information submitted by GSK in response to the [FDA's] requests.”

The approval puts GSK's new drug in a fight for patients whose choices include Novo's Victoza and AstraZeneca's Byetta/Bydureon. BMS ceded it's interest in Byetta/Bydureon last year.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.